Table 4.
Distribution of Therapies for Men Diagnosed with Invasive Male Breast Cancer 2003-2004
| In-situ Wt % (n) | Stage I-III Wt % (n) | Stage IV Wt% (n) | Unknown stage Wt% (n) | |
|---|---|---|---|---|
| Therapy | ||||
| No adjuvant therapy | 90 (52) | 30 (120) | 23 (8) | 53 (14) |
| Chemotherapy only | 0 | 10 (36) | 24 (8) | 4 (1) |
| Chemotherapy + hormone | 0 | 29 (112) | 19 (7) | 16 (4) |
| Hormone only | 10 (6) | 31 (124) | 34 (13) | 27 (7) |
| Hormones only | ||||
| Tamoxifen | 100 (6) | 76 (95) | 30 (4) | 72 (5) |
| Aromatase Inhibitor | 0 | 15 (19) | 38 (5) | 28 (2) |
| Tamoxifen + AI | 0 | 7 (8) | 25 (3) | 0 |
| Other Hormones | 0 | 2 (2) | 7 (1) | 0 |
| Chemotherapeutic Agents | ||||
| Anthracycline + taxane (+/- other chemo) | 46 (67) | 12 (2) | 20 (1) | |
| Anthracycline + other chemo (not taxane) | 34 (51) | 0 | 80 (4) | |
| Taxane + other chemo (not anthracycline) | 3 (23) | 57 (8) | 0 | |
| Other chemo (not anthracycline or taxane) | 15 (23) | 6 (1) | 0 | |
| Anthracycline only | 1 (2) | 0 | 0 | |
| Taxane only | 1 (1) | 25 (4) | 0 | |